Introduction

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in the United States. It still is one of the most rapidly progressive and deadly malignancies worldwide because of the marked tumour resistance to treatment, and the lack of specific early symptoms resulting in advanced stage at diagnosis.

The management of patients with pancreatic carcinoma depends on the stage of the disease. Surgical resection followed by adjuvant therapy is the standard of care for patients diagnosed with resectable disease. However, at diagnosis, only 20% of patients fulfill the resectability criteria. At clinical presentation, 30-40% of patients are affected by a locally advanced cancer due to the abutment of the celiac axis, aortic invasion, superior mesenteric artery encasement or retroperitoneal involvement.

In spite of neoadjuvant treatments (chemotherapy- or chemoradiation therapy) are advocated for locally advanced PDAC, no randomized phase III trials have been carried out to confirm evident clinical benefit. The randomized phase II PRODIGE trial evaluated FOLFIRINOX versus gemcitabine alone in patients with metastatic pancreatic cancer and good performance status: a dramatic improvement in both median progression-free survival and median overall survival in

Abstract

Pancreatic ductal adenocarcinoma may present as locally advanced disease in a significant percentage of patients. Recently, the potent FOLFIRINOX regimen was shown to significantly prolong survival in advanced pancreatic ductal adenocarcinoma. We herein report a case of complete tumor response after FOLFIRINOX treatment of a locally advanced pancreatic cancer that was successfully resected.

A 68-year-old woman was hospitalized in July 2014, for a 2-months history of right abdominal pain and weight loss. Abdominal US and CT showed a 3 cm mass involving the uncinated process of the pancreas and the retroperitoneal tissue with a pathologically enlarged left para-aortic nodes until iliac artery bifurcation. Ca 19-9 levels were 159.2 U/mL (normal value <37 U/mL). US-guided percutaneous biopsy of the mass showed poorly differentiated adenocarcinoma of the pancreas, and the patient was referred to neo-adjuvant therapy with FOLFIRINOX (6 cycles). Ca 19-9 serum levels normalized and CT examination showed reduction of the tumor (2.3 cm) together with para-aortic lymph nodes (<1 cm). 18-FDG PET/CT did not show any pathological uptake of the radiotracer. In December 2014, the patient underwent pylorus-preserving pancreaticoduodenectomy. Pathological examination did not show residual cancer cells, and no adjuvant therapy was administered. Sixteen months after surgery, brain metastasis occurred in absence of other sites of recurrence. Pathological examination of resected specimen confirmed brain metastasis from pancreatic adenocarcinoma. One month later, CT-scan showed multiple brain metastases, treated with palliative stereotactic radiotherapy. Currently, the patient is alive 22 months after pancreatic resection.

Although rare, complete pathologic response of pancreatic adenocarcinoma after neoadjuvant therapy may occur, but this does not mean cure because tumor’s recurrence may happen.

Keywords: FOLFIRINOX; Neoadjuvant chemotherapy; Pancreas; Pancreatic cancer; Pathological response
favour of the group receiving FOLFIRINOX was seen [5]. However, complete pathological response after chemotherapy in advanced pancreatic cancer is a very rare event. We report a case of a complete pathological response after FOLFIRINOX treatment in a patient with advanced pancreatic adenocarcinoma, who subsequently experienced brain metastases.

Case Presentation

A 68-year-old woman with a 2-months history of right abdominal pain and weight loss underwent abdominal ultrasonography that revealed a solid mass in the uncinated process of the pancreas. Abdominal computed tomography (CT) confirmed a 3 x 2 cm mass in the uncinated process, infiltrating the posterior fat planes, with pathologic, enlarged para-aortic nodes until iliac artery bifurcation (Figure 1). The patient was referred to our Institution in July 2014. Routine laboratory examinations were in the normal range; a mild increase of the tumor marker Ca 19-9 was observed (144 U/mL, normal value <37 UI/mL). Percutaneous US-guided biopsy of the lesion showed a poorly differentiated adenocarcinoma. According to these results, the patient underwent neoadjuvant therapy consisting in 5 cycles of chemotherapy with FOLFIRINOX regimen (irinotecan 180 mg/m² on day 1, oxaliplatin 85 mg/m² on day 1, leucovorin 400 mg /m² on day 1 and 5 - fluorouracil 2400 mg /m² continuous infusion over 46 hours every 15 days) from August to October 2014. No dose reduction was required. Major toxicity during the whole treatment was asymptomatic neutropenia G3. Restaging CT-scan showed reduction of pancreatic tumor (23 x 12 mm) and of para-aortic lymph-nodes (< 1 cm) (Figure 2), 18-FDG positron emission tomography (PET) did not show pathologic uptake of the radiotracer. Serum Ca 19-9 levels dropped to 4.4 U/mL. Based on radiological down-staging, surgical resection was planned. At laparotomy, in December 2014, no metastatic lesions or major vessels invasion were found. A relevant grade of fibrosis was observed during the dissection. Frozen section examination of omental and para-aortic nodes were negative. So, pylorus-preserving pancreaticoduodenectomy was performed. The post-operative course was uneventful and the patient was discharged on post-operative day 9. The pathological staging was pT0N0M0 with absence of neoplastic cells both in the specimen and in all examined lymph nodes. No adjuvant treatment was performed. Sixteen months after surgery, the patient showed lapses of memory, apraxia, gait imbalance and weakness in the right leg. Brain CT showed a hypodense, 23-mm lesion with surrounding oedema in the frontal region, suggesting a metastatic lesion (Figure 3). CT scan of the thorax and abdomen did not show signs of recurrent disease, and the patient underwent excision of the cerebral mass. Pathological examination revealed poorly differentiated adenocarcinoma consistent with metastasis from a primary pancreatic carcinoma. One month after surgery, brain CT showed multiple metastatic nodules, and stereotactic radiotherapy was started. Thoracic and abdominal CT-scan examination does not show signs of local or other sites of recurrence. The patient is currently alive 22 months after pancreatic resection.

Discussion

We presented a very uncommon case of locally advanced pancreatic cancer (PC) treated with neoadjuvant therapy, that completely disappeared at pathological examination of resected specimen. Unfortunately, tumour recurred in the brain and progressed despite stereotactic radiotherapy. Neo-adjuvant therapy (i.e. chemotherapy or chemoradiation) and the type of combination therapy have been suggested for locally advanced PC even if its role in clinical practice remains unclear [6].

A new era in the treatment of advanced PC was born in 2003, when an open phase I study on the feasibility of a combination therapy consisting of 5-FU/leucovorin plus oxaliplatin and irinotecan (FOLFIRINOX) for the treatment of patients with metastatic solid tumors was published [7]. The study showed antitumor activity in two patients with PC. Later II phase trial specifically addressed patients with advanced and metastatic PC, showing promising results [8]. The randomized phase III PRODIGE trial evaluated FOLFIRINOX versus gemcitabine alone in patients with metastatic PC and good performance status: a dramatic improvement in both median
progression-free survival and median overall survival in favour of the group receiving FOLFIRINOX was seen [9].

Radiotherapy approaches, with or without chemotherapy, have been frequently used in this subset of patients [10]. A meta-analysis including 11 studies with 794 patients with locally advanced PC, examined the use of radio-therapeutic approaches and demonstrated that overall survival was better with chemoradiation compared to radiotherapy alone [11].

Due to its efficacy in advanced PC, FOLFIRINOX regimen has been tested in the neoadjuvant setting of locally advanced, non-metastatic adenocarcinoma.

Preliminary results in small groups of patients with border-line resectable PC showed that the treatment was safe and resulted in a 67% resection rate and a median survival time of 22 months (12). A recent systematic review of Rombouts et al. [13] collected fourteen studies with 365 patients treated with FOLFIRINOX; 57% of the patients (n=208) underwent also radiotherapy. Resectability rate was 28%, R0 resection rate was 77% and overall median survival time ranged from 8.9 to 25.0 months.

Two meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced PC have been published in the last 2 years [14,15]. Petrelli et al. [14] collected 13 studies for a total of 253 patients. After treatment, 43% of patients underwent resection with 39.4% of R0 resections. Median survival time was reported in only 3 studies and ranged from 13.7 and 24.2 months). The meta-analysis of Suker et al. [15] included 11 studies and reported survival outcome of 315 patients. Resectability rate ranged from 0% to 43%, R0 resection ranged from 50% to 100%, and median survival time was 24.2 months.

A large, single centre experience of FOLFIRINOX regimen in locally advanced PC reported a resectability rate of 50.8% (292/575 patients) with a median survival time of 15.3 months [16].

Despite the retrospective nature of the studies, these data confirm that FOLFIRINOX therapy is a promising regimen for locally advanced adenocarcinoma of the pancreas, but further prospective studies are needed in order to evaluate long-term outcome of these patients. Complete pathological response after FOLFIRINOX therapy is infrequent. Rombouts et al. [13] found 6 complete pathologic responses in 85 (7%) resected specimens, but outcome of these patients is not reported. Gostimir et al. [17] described a case of patient treated with FOLFIRINOX for border-line resectable PC. After pancreaticoduodenectomy, final pathological analysis revealed no evidence of residual adenocarcinoma, and the patient is alive and disease-free 15 months after surgery. Hartlapp et al. [18] reported a case of complete pathologic response of a locally advanced PC treated with 4 cycles of FOLFIRINOX. After resection, adjuvant chemotherapy with nab-paclitaxel/gemcitabine was administered for three months. The patient is disease free 25 months after initial diagnosis. Turner et al. [19] described the case of a complete radiological response with chemotherapy and radiotherapy of a locally advanced PDAC; 6 months after surgery a CT scan showed no signs of recurrence.

Valeri et al. [20] reported a case of complete pathological response after 8 cycles of FOLFIRINOX and the patient is alive and without evidence of disease 14 months after surgery.

Brain metastasis after resection for PC as single site of recurrence is very uncommon. In 2004, El Kamar et al. [21] reported a patient with stage IV PC who developed brain metastases and collected 40 similar cases from the Literature: only 13 of which were diagnosed ante-mortem. More recently, Japanese Authors reported a case of patient with stage IV PC who initially responded to FOLFIRINOX therapy, but subsequently progressed with multiple brain metastases and died 7 months after the first diagnosis [22].

Our patient showed a complete pathologic response to FOLFIRINOX, but 16 months after pancreaticoduodenectomy brain metastasis occurred. Despite resection of recurrence, multiple brain metastases reappeared. To our knowledge, this is the first case of a single brain recurrence after pancreatic resection and complete disappearance of primary tumor.

In conclusion, FOLFIRINOX neoadjuvant therapy for locally advanced PC may allow resection rate in a significant percentage of patients. Complete pathologic response is a rare event and does not mean “cure”. More studies and more informations about recurrence details and survival are needed.

References


